Literature DB >> 1986081

Hematin therapy for the neurologic crisis of tyrosinemia.

J M Rank1, A Pascual-Leone, W Payne, M Glock, D Freese, H Sharp, J R Bloomer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1986081     DOI： 10.1016/s0022-3476(05)81867-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  6 in total

1.  Neurological crisis in hereditary tyrosinaemia and complete reversal after liver transplantation.

Authors:  G Noble-Jamieson; N Jamieson; P Clayton; S Bailey; M Ryalls; N D Barnes
Journal:  Arch Dis Child       Date:  1994-06       Impact factor: 3.791

Review 2.  Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Authors:  Vaithamanithi-Mudumbai Sadagopa Ramanujam; Karl Elmo Anderson
Journal:  Curr Protoc Hum Genet       Date:  2015-07-01

3.  Role of delta-aminolevulinic acid in the symptoms of acute porphyria.

Authors:  D Montgomery Bissell; Jennifer C Lai; Raymond K Meister; Paul D Blanc
Journal:  Am J Med       Date:  2014-11-08       Impact factor: 4.965

4.  Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone.

Authors:  Neslihan Önenli Mungan; Dinçer Yıldızdaş; Deniz Kör; Özden Özgür Horoz; Faruk İncecik; Murat Öktem; Johannes Sander
Journal:  Metab Brain Dis       Date:  2016-05-17       Impact factor: 3.584

5.  Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase.

Authors:  T C Gibbs; J Payan; E M Brett; S Lindstedt; E Holme; P T Clayton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-10       Impact factor: 10.154

6.  Severe neurological crisis in adult patients with Tyrosinemia type 1.

Authors:  Charlotte Dawson; Radha Ramachandran; Samreen Safdar; Elaine Murphy; Orlando Swayne; Jonathan Katz; Philip N Newsome; Tarekegn Geberhiwot
Journal:  Ann Clin Transl Neurol       Date:  2020-08-21       Impact factor: 4.511
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.